A Long-term Extension of Study GNC-401
Phase 2
Terminated
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- GeNeuro Innovation SAS
- Target Recruit Count
- 33
- Registration Number
- NCT05049161
- Locations
- 🇸🇪
Center for Neurology, Academic Specialist Center, Stockholm, Sweden
Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
Phase 2
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- GeNeuro Innovation SAS
- Target Recruit Count
- 41
- Registration Number
- NCT04480307
- Locations
- 🇸🇪
Center for Neurology, Academic Specialist Center, Stockholm, Sweden
Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GeNeuro Innovation SAS
- Target Recruit Count
- 21
- Registration Number
- NCT02452996
- Locations
- 🇩🇪
PAREXEL Early Phase Clinical Unit, Berlin, Germany
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Other: No study treatments administered
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GeNeuro Innovation SAS
- Target Recruit Count
- 25
- Registration Number
- NCT01804660
- Locations
- 🇫🇷
Etablissement Français du Sang Rhône Alpes - 1 route de Taninges, Annemasse, France
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
Completed
- Conditions
- Multiple Sclerosis (MS)Relapsing-Remitting MSPrimary Progressive MSSecondary Progressive MSClinically Isolated Syndrome (CIS)
- Interventions
- Other: No study treatments administered - blood draws only
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GeNeuro Innovation SAS
- Target Recruit Count
- 58
- Registration Number
- NCT01804647
- Locations
- 🇫🇷
Hospices civils de Lyon - Service de Neurologie A - 59 Boulevard Pinel, Bron cedex, France
🇫🇷CHU Timone - Service de Neurologie et CRMBM CNRS 7339 - 264, rue Saint Pierre, Marseille Cedex 5, France
🇪🇸Hospital Universitari and Research Institute Vall d'Hebron - Servicio de Neuroimunologia de Nuestro Centro - Pg. Vall d'Hebron 119-129, Barcelona, Cataluna, Spain
First-in-Human Study With GNbAC1 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: GNbAC1Biological: GNbAC1 placebo
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GeNeuro Innovation SAS
- Target Recruit Count
- 33
- Registration Number
- NCT01699555
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Phase 2
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: GNbAC1 placeboBiological: GNbAC1
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- GeNeuro Innovation SAS
- Target Recruit Count
- 10
- Registration Number
- NCT01639300
- Locations
- 🇨ðŸ‡
University Hospital Basel, Basel, Switzerland
🇨ðŸ‡Hopitaux Universitaires de Genève - HUG, Geneva, Switzerland
© Copyright 2025. All Rights Reserved by MedPath